

November 15, 2023

Cuorips Inc.

Announcement of Presentation at AHA (American Heart Association) Scientific Session

We are pleased to announce that the results of the investigator-initiated clinical trial for the first human transplantation of iPS cell-derived cardiomyocyte patches ("iPS cardiomyocyte patches") conducted by a research group at the Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine were presented at a Scientific Session of the AHA (American Heart Association). The results of the clinical trial were presented at a scientific session of the American Heart Association (AHA).

Founded in 1924 by cardiologists, the American Heart Association (AHA) is the world's largest medical society in the field of cardiology. It is the world's premier cardiovascular society, where attendees are exposed to cutting-edge research and clinical techniques through presentations and discussions by the world's leading cardiovascular physicians, and is regarded as the most difficult scientific meeting to be accepted for research presentations.

The abstract of the presentation is as follows

Title: First in Human Clinical Trial of Human Induced Pluripotent Stem Cell-Derived Cardiac Patches for Ischemic Heart Failure Patients

Session: Scientific

Format: Oral Session (Oral Presentation)

Presenter: Takuji Kawamura (Assistant Professor, Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine)

Presentation: Confirmation of Safety and Future Possibilities of Transplantation of iPS Cardiomyocyte Cell Patches to Three Patients

Date: November 13, 2023

Place: Pennsylvania Convention Center, Philadelphia, Pennsylvania, USA

We at Cuorips, will make every effort to deliver these patches to patients all over the world as soon as possible. These patches have drawn worldwide interest owing to the acceptance for oral presentation at the above prestigious conference.

(please contact)

cuo_ir@cuorips.co.jp